Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02398604 · ClinicalTrials.gov registry record · Phase 1
Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome
A Phase 1 study, sponsored by Longeveron.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02398604 is a Phase 1 study that was terminated before completion, run by Longeveron. The registered enrollment target is 5 participants.
The verdict
NCT02398604, a Phase 1 study, was terminated before completion, sponsored by Longeveron.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.
Interventions
- DRUG Placebo
- DRUG Allo-hMSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02398604
The ClinicalTrials.gov registry entry for NCT02398604 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Longeveron, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02398604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02398604 about?
NCT02398604 is a clinical study titled "Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome". This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.
What is the current status of trial NCT02398604?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2015-04. Estimated completion is 2019-03.
What interventions are being tested in trial NCT02398604?
The interventions under investigation include: Placebo (DRUG), Allo-hMSCs (DRUG).
Who is sponsoring clinical trial NCT02398604?
This trial is sponsored by Longeveron, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.